Diabetes News and Research

Latest Diabetes News and Research

Annals of Neurology publishes Diamyd Medical´s NP2 Enkephalin Phase I results in cancer pain

Diamyd Medical´s Phase I clinical trial results evaluating the safety and efficacy of the candidate drug NP2 Enkephalin to treat intractable cancer pain has been published in the medical journal Annals of Neurology.

11 Apr 2011

Lonza, Roche sign agreement to commercialize MycoTOOL PCR-test

Roche and Lonza announced today that they have entered into a co-exclusive distribution agreement for the commercialization of Roche's MycoTOOL mycoplasma PCR assays.

11 Apr 2011

New point-of-care trial can reduce cost and length of studies

Doctors at the Veterans Affairs Boston Healthcare System are testing a new kind of clinical trial that's not only less costly but guides doctors to switch to the best treatment even before the trial is completed.

11 Apr 2011

Gilenya can reduce risk of disability progression in patients with RRMS

A new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

11 Apr 2011

Investigational drug effective for patients with obesity

An investigational combination of drugs already approved to treat obesity, migraine and epilepsy produced up to a 10 percent weight loss in obese individuals participating in a one-year clinical trial, according to researchers at Duke University Medical Center.

11 Apr 2011

New weight loss pill - combination of two existing drugs

According to the latest research on obesity treatments there is now a new weapon in the battle for weight loss. It combines two existing drugs that have resulted in twice as much weight loss as the only approved long-term anti-obesity medication.

10 Apr 2011

Increased levels of plasma renin activity protein may predict major cardiovascular event in high-risk patients

Increased levels of a protein that helps regulate the body's blood pressure may also predict a major cardiovascular event in high-risk patients, according to a study led by St. Michael's Hospital's cardiovascular surgeon Subodh Verma. Measuring the amount of the protein, known as plasma renin activity (PRA), in the blood stream may give doctors another tool to assess a patient's risk and help prevent a heart attack or stroke.

8 Apr 2011

Reduction in alcohol prices increases alcohol-related mortality

Does a reduction in the price of alcohol result in an increase in deaths due to alcohol? This was the subject of a study following a significant reduction in taxes in Finland in 2004 (30% for spirits, 3% for wine).The abolition of import quotas by the EU in 2004 also made it possible to import from other member countries and this led to an increase of approximately 10% in alcohol consumption in Finland.

8 Apr 2011

Key regulator of fat cell development may provide a target for obesity and diabetes drugs

New research by scientists at The Scripps Research Institute and collaborating institutions has identified a key regulator of fat cell development that may provide a target for obesity and diabetes drugs.

8 Apr 2011

FDA grants tentative approval for Hi-Tech Pharmacal's generic Combigan ANDA

Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted tentative approval for the Company's Abbreviated New Drug Application, (ANDA) for brimonidine tartrate with timolol maleate ophthalmic solution, the generic for Allergan's Combigan® ophthalmic solution which had sales of $108 million for the 12 months ended December 2010 according to IMS sales data.

8 Apr 2011

FDA accepts Antares Pharma's Anturol NDA for filing, assigns PDUFA date

Antares Pharma, Inc. today announced the New Drug Application (NDA) for Anturol® Gel in patients with overactive bladder (OAB) was accepted for filing for review by the U.S. Food and Drug Administration (FDA). Anturol is an oxybutynin gel incorporating Antares' ATD Gel technology.

8 Apr 2011

Survivors of severe critical illness requiring intensive care do not regain physical or psychological health

A unique and richly detailed long-term study of survivors of severe critical illness requiring intensive care found that even those who were previously healthy, young and working did not regain the physical or psychological health they had before their illness.

8 Apr 2011

Two new studies on Veterans Affairs health care system

As recently as the 1990s, the Veterans Affairs health care system had a subpar reputation for quality, but two new studies of standard quality metrics, both led by Amal Trivedi, assistant professor of community health at Brown University and a physician at the Providence VA Medical Center, show that the system that cares for more than 5 million patients has improved markedly in the last decade.

8 Apr 2011

Biochemical battle of the bulge: New developments

Dozens of researchers in the coming days will lay out what's around the corner in the biochemical battle of the bulge as part of the Experimental Biology 2011 conference in Washington, D.C.

8 Apr 2011

Caffeine disrupts glucose metabolism and may contribute to type 2 diabetes

A growing body of research suggests that caffeine disrupts glucose metabolism and may contribute to the development and poor control of type 2 diabetes, a major public health problem.

8 Apr 2011

First trial to test shared decision making for weight-loss surgery

A video-based decision aid helped severely obese people to make more informed choices about bariatric surgery and reach more certainty about them, according to a trial involving 152 Group Health patients, e-published in Obesity in advance of print. This randomized controlled trial is the first to test shared decision making for weight-loss surgery.

8 Apr 2011

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye, an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema.

8 Apr 2011

Refined carbohydrates create an ill and obese population

When it comes to feeding a body well, we've all been told we need proteins, fats and carbohydrates. For years, many of those we trust for health information have told us that the foundation of our diet should primarily consist of carbohydrates, namely, grains, breads and pastas.

8 Apr 2011

Longer looks: Could Ryan's plan be a pitfall for Democrats?; the cost of military health care; revealing more about doctors' billing practices

Every week, reporter Jessica Marcy selects interesting reading from around the Web.

8 Apr 2011

New insight into acute pancreatitis

Timing is everything. That's especially true when it comes to the activation of enzymes created by the pancreas to break down food. When the timing is right, those enzymes are activated only when they reach the gut, where they get to work releasing and distributing nutrients that we need to survive.

8 Apr 2011